Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

I have signed a few employment contracts in my career. Signing a legal document always makes me nervous. Did I forget to add something, was there something in the fine print I missed, should I have clarified a clause, what happens if I break a clause or cannot fulfill the contract obligations?

I spoke with Andrea Liberatore, JD, to navigate these questions and explain what to look for in a contract. 

Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids.

MMWR April 14, 2023

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.

A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.

In medicine, a field where burnout is becoming the norm, there is much promotion of the idea of work-life balance. In reality, the scales between work and life aren’t really balanced. Is the potential for change on the horizon?

Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.

I recently sat down with Dr. Daniel Battafarano, chair of the ACR’s Workforce Solutions Committee, to discuss workforce study findings, their impact on the next few years, and proposed interventions to address these issues.

During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?  A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur

As I was training as a rheumatologist, I found myself drawn to rheumatologic disorders in older patients. In particular, I was intrigued by programmatic development that could improve both disease outcomes and older adults’ quality of life. This was not the “sexiest” topic in rheumatology and it was hard to figure out how to get started. I was extremely fortunate to find a mentor.

Sensitive women and stoical men are the prevalent images of people in chronic pain. Unwarranted differences in medical treatment may result, as a University of Gothenburg doctoral thesis emphasizes.

Fibromyalgia is a mysterious chronic pain disorder that is difficult to treat. Its causes are also still largely in the dark.